Caprion-HistoGeneX, a Montreal-based global provider of specialized precision medicine lab services, has rebranded as CellCarta. The company’s mission is mapping the content and function of human cells to enable and accelerate the evolution of personalized precision medicine.
 
The new name stems from the 2019 combination of CRO Caprion Biosciences, which specializes in immunology and proteomics services, and HistoGeneX, a provider of histopathology and genomics services based in Antwerp.
 
CellCarta recently expanded its scientific capabilities and geographic presence with the acquisitions of Nova Scotia-based Clinical Logistics Inc. and California-based Mosaic Laboratories LLC. As a result, CellCarta is able to serve the global clinical trial requirements of its pharmaceutical and biotech clients with facilities in the U.S., Canada, Europe and China. 
 
“Our mission is to be the global partner of choice for biopharmaceutical companies seeking precision medicine solutions to help ensure a healthier future for us all,” said Martin LeBlanc, CEO of CellCarta. “By uniting our diverse teams of scientists across the world under a common brand identity, we aim to articulate a single message aligned with our shared set of fundamental values focused on scientific excellence, a collaborative mindset and a commitment to deliver high quality results to our partners. It also further reinforces our commitment to provide our clients with a broad and integrated set of services under a single organization.”